#XebioHoldings

Resolved to issue and grant 187 stock-based compensation options to two directors (foreign directors excluded), comprising 18,700 shares of common stock as the target shares, with 100 shares per option. Grant date: 2026/09/15; exercise period: 2026/09/16 to 2056/09/15. Exercise price set at fair value on grant date, rounding down fractions, capital increase capped at half.

Xebio Holdings will issue 2,180 new share subscription rights on June 12, 2026, with a total of 58 recipients including directors and employees. The exercise price is 107,000 yen, and allocation to eligible recipients has been finalized.

Xebio Holdings will allocate 2,180 stock acquisition rights to 58 individuals on June 12, 2026, with an exercise period from June 13, 2028, to June 12, 2033. The purpose is to incentivize performance improvement and increase corporate value.

Xebio Holdings announced its fiscal year ending March 2026 results, with sales of ¥253.2 billion (YoY +0.7%) and a net loss of △2,423 million yen. The company is working on business restructuring and profitability improvement while responding to changes in domestic and international market environments.

Xebio Holdings recorded an extraordinary loss of 7,373 million yen for the fiscal year ending March 2026 and revised the full-year net income forecast to a 2,141 million yen loss.

Xebio Holdings resolved changes to directors effective June 26, 2026. Mr. Tsuyoshi Fujisawa will retire, and other directors are scheduled for reappointment.

For the third quarter of the fiscal year ending March 2026, net sales were ¥188.803 billion (0.3% YoY increase), operating income was ¥2.494 billion (58.9% YoY decrease), and net income attributable to owners of parent was ¥866 million (77.9% YoY decrease).